Alps Group Inc
No enriched coverage for $ALPS in the last 7 days.
No SEC Form 4 filings for $ALPS in the last 30 days.
See all $ALPS insider activity →Alps Group Inc (ALPS) reported results for the year ended March 31, 2026 and said it completed its business combination with Globalink in October 2025, starting Nasdaq Global Market trading under ticker ALPS. The company reported 44% year-over-year revenue growth and said it advanced its cellular therapy pipeline and R&D focus.
Alps Group Inc (Nasdaq: ALPS) reported fiscal year 2026 results ended March 31, 2026. Revenue rose 44% to $4.9 million, gross profit to $1.6 million, while net loss narrowed to $2.1 million. The company also said it completed a business combination with Globalink in Oct 2025 and began Nasdaq trading under ALPS, and updated its cellular therapy and diagnostics programs.
ALPS Group Inc (NASDAQ:ALPS) saw short interest fall sharply in May, dropping 82.5% to 5,804 shares as of May 15 from 33,182 on April 30, according to the report. The short-interest ratio was 0.2 days. ALPS shares traded down 1.3% to $0.76. Weiss Ratings initiated coverage with a “sell (e+)” rating.
Recent ALPS coverage spans earnings, financial news and market movers.
The article is a post-combination financial update with revenue growth and pipeline progress, which can shift near-term sentiment and valuation expectations.
The filing-style earnings update and business progress (MyImmune process validation progress, WGS accreditation, PDO platform) can shift near-term sentiment, but scale remains small.
Short-covering dynamics may have eased, but the stock remains very low-liquidity and valuation-sensitive.
ALPS Group experienced a notable after-market gain, indicating short-term bullish sentiment.
ALPS Group reported strong Q3 earnings, contributing to the Nasdaq's 1% increase. The positive earnings suggest improved financial health and growth prospects.
alphai scores every news story that mentions ALPS with an AI model for sentiment and relevance, and aggregates insider trades from Alps Group Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Alps Group Inc (ALPS) reported results for the year ended March 31, 2026 and said it completed its business combination with Globalink in October 2025, starting Nasdaq Global Market trading under ticker ALPS. The company reported 44% year-over-year revenue growth and said it advanced its cellular therapy pipeline and R&D focus.
2 min readAlps Group Inc (Nasdaq: ALPS) reported fiscal year 2026 results ended March 31, 2026. Revenue rose 44% to $4.9 million, gross profit to $1.6 million, while net loss narrowed to $2.1 million. The company also said it completed a business combination with Globalink in Oct 2025 and began Nasdaq trading under ALPS, and updated its cellular therapy and diagnostics programs.
6 min readALPS Group Inc (NASDAQ:ALPS) saw short interest fall sharply in May, dropping 82.5% to 5,804 shares as of May 15 from 33,182 on April 30, according to the report. The short-interest ratio was 0.2 days. ALPS shares traded down 1.3% to $0.76. Weiss Ratings initiated coverage with a “sell (e+)” rating.
2 min readThis article details the after-market performance of 12 healthcare stocks on Monday. It lists both gainers, such as ALPS Group and NeuroOne Medical Technologies, and losers, including Anebulo Pharmaceuticals and Invivyd, along with their respective percentage changes and market capitalizations.
2 min readU.S. stocks traded higher this morning, with the Nasdaq Composite gaining 1% on Monday. Following the market opening Monday, the Dow traded up 0.04% to 47,583.87 while the NASDAQ rose 1.01% to 23,964.61. The S&P 500 also rose, gaining, 0.48% to 6,872.88. Consumer discretionary shares jumped by ...
4 min read
